Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) issued its quarterly earnings data on Wednesday. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01), Zacks reports.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock traded up $0.03 during midday trading on Thursday, reaching $1.02. 2,862 shares of the company were exchanged, compared to its average volume of 33,769. The company has a market capitalization of $41.03 million, a price-to-earnings ratio of -0.68 and a beta of -0.80. The firm’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $1.12. Barinthus Biotherapeutics has a 1 year low of $0.80 and a 1 year high of $4.16.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price target on shares of Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, January 13th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.